The Filing Desk

Celularity vs Scilex

Celularity CELU · Scilex SCLX · Pharmaceuticals

Scilex reported revenue of $30 million in fiscal 2025, about the same as Celularity's $26 million in fiscal 2025. Celularity's revenue fell 51.0% in its latest year, and Scilex's fell 46.5%. Celularity had an operating margin of -230.9%, against -1143.7% at Scilex.

Side by side

CelularityScilex
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$26M$30M
Revenue growth−51.0%−46.5%
Revenue growth a year, last 5 years13.1%5.1%
Gross margin24.4%—
Operating margin−230.9%−1,143.7%
Net margin−345.4%−1,236.4%
Free cash flow—$4M
Free cash flow margin—12.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count16.9%108,662.9%
Last close$0.47$0.65
P/E at the last close——
Insider trades, last 12 months—sold $12.8 million
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CelularityScilex
Operating margin
Percent of revenue
CelularityScilex
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CelularityScilex

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celularity and Scilex pages.